Systemic Lupus Erythematosus - Pipeline Review, H2 2017

Date: November 14, 2017
Pages: 427
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S6FFC1B00C0EN
Leaflet:

Download PDF Leaflet

Systemic Lupus Erythematosus - Pipeline Review, H2 2017
Systemic Lupus Erythematosus - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2017, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 28, 25, 40, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Systemic Lupus Erythematosus - Overview
Systemic Lupus Erythematosus - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Systemic Lupus Erythematosus - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
AbbVie Inc
Ablynx NV
ACEA Biosciences Inc
AiCuris GmbH & Co KG
Amgen Inc
Asahi Kasei Pharma Corp
Atlantic Bio Sci LLC
Aurinia Pharmaceuticals Inc
Bio-Path Holdings Inc
Biogen Inc
Biotest AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Celgene Corp
Corestem Inc
CuraVac Inc
Deltanoid Pharmaceuticals Inc
Domainex Ltd
Eisai Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Galapagos NV
Genentech Inc
Genosco Inc
Genovax Srl
Gilead Sciences Inc
GlaxoSmithKline Plc
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Idorsia Ltd
Immungenetics AG
Immunomedics Inc
Immunwork Inc
Immupharma Plc
Invion Ltd
Janus Biotherapeutics Inc
Johnson & Johnson
K-Stemcell Co Ltd
Karyopharm Therapeutics Inc
KPI Therapeutics Inc
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
LSK BioPartners Inc
MacroGenics Inc
MedAnnex Ltd
Medestea Research & Production SpA
MedImmune LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
Mount Tam Biotechnologies Inc
Nektar Therapeutics
Neovacs SA
Nippon Chemiphar Co Ltd
Novartis AG
Nuevolution AB
Omeros Corp
Pfizer Inc
Principia Biopharma Inc
Ra Pharmaceuticals Inc
RedHill Biopharma Ltd
Sarepta Therapeutics Inc
SBI Biotech Co Ltd
Takeda Pharmaceutical Co Ltd
TheraMAB LLC
TxCell SA
UCB SA
Xencor Inc
XTL Biopharmaceuticals Ltd
Zai Lab Ltd
Systemic Lupus Erythematosus - Drug Profiles
(clarithromycin + clofazimine + rifabutin) - Drug Profile
abatacept - Drug Profile
ABS-11 - Drug Profile
AC-058 - Drug Profile
ACY-1083 - Drug Profile
ACY-738 - Drug Profile
aldesleukin - Drug Profile
aldesleukin - Drug Profile
AMG-557 - Drug Profile
AMG-570 - Drug Profile
amiselimod hydrochloride - Drug Profile
anifrolumab - Drug Profile
Annexuzlimab - Drug Profile
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile
APT-602 - Drug Profile
AT-791 - Drug Profile
atacicept - Drug Profile
baricitinib - Drug Profile
bee venom [Apis mellifera] allergen extract - Drug Profile
belimumab - Drug Profile
belimumab + rituximab - Drug Profile
BI-655064 - Drug Profile
BI-705564 - Drug Profile
BIIB-059 - Drug Profile
BIIB-068 - Drug Profile
Bispecific Monoclonal Antibody to Inhibit CD22 and CD20 for Autoimmune Disorders and Oncology - Drug Profile
BL-5923 - Drug Profile
BMS-986165 - Drug Profile
bortezomib - Drug Profile
BT-063 - Drug Profile
C-15231A - Drug Profile
CC-90008 - Drug Profile
Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile
Cellular Immunotherapy for Epstein-Barr Viral Infections, Multiple Sclerosis and Systemic Lupus Erythematosus - Drug Profile
Cellular Immunotherapy to Target CD19 for Oncology and Immunology - Drug Profile
cenerimod - Drug Profile
CS-20AT04 - Drug Profile
dalazatide - Drug Profile
dapirolizumab pegol - Drug Profile
DMXD-011 - Drug Profile
DP-001 - Drug Profile
Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile
Drugs to Inhibit BAFF and APRIL for Systemic Lupus Erythematosus - Drug Profile
E-6446 - Drug Profile
edratide - Drug Profile
ENTX-LN - Drug Profile
evobrutinib - Drug Profile
faralimomab - Drug Profile
filgotinib - Drug Profile
forigerimod acetate - Drug Profile
GDC-0853 - Drug Profile
GNKS-356 - Drug Profile
GS-9876 - Drug Profile
GX-101 - Drug Profile
HCI-1401 - Drug Profile
HE-33 - Drug Profile
HL-161 - Drug Profile
iberdomide hydrochloride - Drug Profile
ICP-022 - Drug Profile
IL-233 - Drug Profile
IMP-10 - Drug Profile
INV-103 - Drug Profile
INV-17 - Drug Profile
INV-88 - Drug Profile
ixazomib citrate - Drug Profile
JB-6121 - Drug Profile
JNJ-0839 - Drug Profile
JNJ-56022473 - Drug Profile
KPT-350 - Drug Profile
lenabasum - Drug Profile
lulizumab pegol - Drug Profile
MEDI-7734 - Drug Profile
MGD-010 - Drug Profile
milatuzumab - Drug Profile
mizoribine - Drug Profile
NC-2400 - Drug Profile
NCS-613 - Drug Profile
NKTR-358 - Drug Profile
NUE-7770 - Drug Profile
obinutuzumab - Drug Profile
OMS-721 - Drug Profile
P-Dex - Drug Profile
PF-06823859 - Drug Profile
poseltinib - Drug Profile
prexigebersen - Drug Profile
PRN-1008 - Drug Profile
RA-101495 - Drug Profile
RCT-18 - Drug Profile
RSLV-132 - Drug Profile
RSLV-133 - Drug Profile
SBI-9674 - Drug Profile
SKIO-703 - Drug Profile
SM-03 - Drug Profile
SM-934 - Drug Profile
Small Molecule to Agonize CD11b for Systemic Lupus Erythematosus - Drug Profile
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile
Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders - Drug Profile
Small Molecules for Respiratory and Immunology - Drug Profile
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile
Small molecules to Inhibit PAD for Autoimmune Diseases, Multiple Sclerosis and Oncology - Drug Profile
Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology, Oncology and Cardiovascular Disease - Drug Profile
Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
Synthetic Peptides for Systemic Lupus Erythematosus - Drug Profile
TAB-08 - Drug Profile
TAK-079 - Drug Profile
TAM-01 - Drug Profile
TE-2324 - Drug Profile
tofacitinib citrate - Drug Profile
ustekinumab - Drug Profile
Vaccine for Systemic Lupus Erythematosus - Drug Profile
Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile
venetoclax - Drug Profile
VISTA-Ig - Drug Profile
vobarilizumab - Drug Profile
voclosporin - Drug Profile
WITH-1101 - Drug Profile
XL-499 - Drug Profile
XmAb-5871 - Drug Profile
ZL-1101 - Drug Profile
Systemic Lupus Erythematosus - Dormant Projects
Systemic Lupus Erythematosus - Discontinued Products
Systemic Lupus Erythematosus - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Systemic Lupus Erythematosus, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H2 2017
Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co KG, H2 2017
Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, H2 2017
Systemic Lupus Erythematosus - Pipeline by Atlantic Bio Sci LLC, H2 2017
Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2017
Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Co, H2 2017
Systemic Lupus Erythematosus - Pipeline by Celgene Corp, H2 2017
Systemic Lupus Erythematosus - Pipeline by Corestem Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Co, H2 2017
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Galapagos NV, H2 2017
Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Genosco Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Genovax Srl, H2 2017
Systemic Lupus Erythematosus - Pipeline by Gilead Sciences Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H2 2017
Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Idorsia Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H2 2017
Systemic Lupus Erythematosus - Pipeline by Immunomedics Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Immunwork Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Invion Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Janus Biotherapeutics Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H2 2017
Systemic Lupus Erythematosus - Pipeline by K-Stemcell Co Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by KPI Therapeutics Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H2 2017
Systemic Lupus Erythematosus - Pipeline by LSK BioPartners Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by MacroGenics Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Medestea Research & Production SpA, H2 2017
Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H2 2017
Systemic Lupus Erythematosus - Pipeline by Merck & Co Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H2 2017
Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Nektar Therapeutics, H2 2017
Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H2 2017
Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Novartis AG, H2 2017
Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H2 2017
Systemic Lupus Erythematosus - Pipeline by Omeros Corp, H2 2017
Systemic Lupus Erythematosus - Pipeline by Pfizer Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by Ra Pharmaceuticals Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by TheraMAB LLC, H2 2017
Systemic Lupus Erythematosus - Pipeline by TxCell SA, H2 2017
Systemic Lupus Erythematosus - Pipeline by UCB SA, H2 2017
Systemic Lupus Erythematosus - Pipeline by Xencor Inc, H2 2017
Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd, H2 2017
Systemic Lupus Erythematosus - Pipeline by Zai Lab Ltd, H2 2017
Systemic Lupus Erythematosus - Dormant Projects, H2 2017
Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..1), H2 2017
Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..2), H2 2017
Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..3), H2 2017
Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..4), H2 2017
Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..5), H2 2017
Systemic Lupus Erythematosus - Discontinued Products, H2 2017
Systemic Lupus Erythematosus - Discontinued Products, H2 2017 (Contd..1), H2 2017

LIST OF FIGURES

Number of Products under Development for Systemic Lupus Erythematosus, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
Ablynx NV
ACEA Biosciences Inc
AiCuris GmbH & Co KG
Amgen Inc
Asahi Kasei Pharma Corp
Atlantic Bio Sci LLC
Aurinia Pharmaceuticals Inc
Bio-Path Holdings Inc
Biogen Inc
Biotest AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Celgene Corp
Corestem Inc
CuraVac Inc
Deltanoid Pharmaceuticals Inc
Domainex Ltd
Eisai Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Galapagos NV
Genentech Inc
Genosco Inc
Genovax Srl
Gilead Sciences Inc
GlaxoSmithKline Plc
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Idorsia Ltd
Immungenetics AG
Immunomedics Inc
Immunwork Inc
Immupharma Plc
Invion Ltd
Janus Biotherapeutics Inc
Johnson & Johnson
K-Stemcell Co Ltd
Karyopharm Therapeutics Inc
KPI Therapeutics Inc
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
LSK BioPartners Inc
MacroGenics Inc
MedAnnex Ltd
Medestea Research & Production SpA
MedImmune LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
Mount Tam Biotechnologies Inc
Nektar Therapeutics
Neovacs SA
Nippon Chemiphar Co Ltd
Novartis AG
Nuevolution AB
Omeros Corp
Pfizer Inc
Principia Biopharma Inc
Ra Pharmaceuticals Inc
RedHill Biopharma Ltd
Sarepta Therapeutics Inc
SBI Biotech Co Ltd
Takeda Pharmaceutical Co Ltd
TheraMAB LLC
TxCell SA
UCB SA
Xencor Inc
XTL Biopharmaceuticals Ltd
Zai Lab Ltd
Skip to top


Systemic Lupus Erythematosus Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 187 pages

Ask Your Question

Systemic Lupus Erythematosus - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: